After a dismal Q3 '25 results and YTD performance, the main question is whether Alexandria Real Estate Equities, Inc. (NYSE: ARE ), a biotech lab/office REIT, will rebound, or whether it has at least reachedBashar is a contributing writer at Seeking Alpha, focusing on Long/Short investment ideas, with a geographic focus in North America. Before that, Bashar worked at an Investment Fund in the United Kingdom. He has a Master's degree in Finance from the Queen Mary University of London and a Bachelor's degree ...

Core Insights - Alexandria Real Estate Equities, Inc. (NYSE: ARE) has reported disappointing Q3 '25 results and year-to-date performance, raising questions about its potential for recovery or if it has reached a low point [1] Financial Performance - The company is categorized as a biotech lab/office REIT, indicating its focus on real estate investments tailored for the biotechnology sector [1] Analyst Background - The article is contributed by a writer with a background in finance and investment, suggesting a level of expertise in analyzing investment opportunities [1]